Glucagon is a 29--amino acid pancreatic hormone that is secreted from the pancreatic α-cells into the portal blood supply in response to hypoglycemia, acting as the counter-regulatory hormone to insulin. Its main biologic effect is the regulation of glucose metabolism by enhancing the synthesis and mobilization of glucose in the liver. There is solid evidence demonstrating that the inhibition of glucagon signaling *in vivo* leads to a reduction of plasma glucose ([@b27-ehp0113-000969]). In addition, glucagon has many extrahepatic effects, such as the increase of lipolysis in adipose tissue, a positive inotropic effect in the heart, a role in the satiety control in the central nervous system, and the regulation of the glomerular filtration rate ([@b3-ehp0113-000969]). In the islets of Langerhans, it participates in the regulation of intraislet hormone, insulin, somatostatin, and glucagon secretion ([@b19-ehp0113-000969]; [@b33-ehp0113-000969]). When insulin secretion from β-cells is impaired, diabetes mellitus develops. In this pathology, the normal physiologic suppression of glucagon secretion from pancreatic α-cells in response to elevated plasma glucose is lost ([@b66-ehp0113-000969], [@b67-ehp0113-000969]). A concomitant decrease in early insulin secretion in response to oral glucose is also observed. These combined defects alter the insulin-to-glucagon ratio, leading to a failure of the normal suppression of endogenous glucose production that occurs after ingestion of oral glucose ([@b16-ehp0113-000969]). This contributes to the elevation of glucose levels in plasma in individuals with impaired glucose tolerance or diabetes.

Despite the great importance of α-cells, little is known about the stimulus secretion coupling and its regulation by other hormones and neurotransmitters. This is partly due to the scarcity of islet tissue and small proportion of α-cells compared with insulin-releasing β-cells. α-Cells contain a specific set of ion channels, including a voltage-dependent Na^+^ channel, responsible for their electrical activity ([@b18-ehp0113-000969]; [@b53-ehp0113-000969]; [@b56-ehp0113-000969]). Consequently, the intracellular calcium ion \[Ca^2+^\]~i~ oscillates at low glucose concentrations ([@b4-ehp0113-000969]; [@b38-ehp0113-000969]). Because of the calcium influx, the exocytotic machinery is initiated and glucagon is released ([@b17-ehp0113-000969]; [@b20-ehp0113-000969]). When the extracellular glucose concentration increases to the level needed for insulin to be released, the frequency of \[Ca^2+^\]~i~ oscillations diminishes and, as a consequence, glucagon release decreases ([@b38-ehp0113-000969]; [@b46-ehp0113-000969]).

Although the endocrine pancreas is not considered a classic estrogen target, estrogen effects on insulin and glucagon secretion and receptors of a classical and nonclassical nature are present in islet cells ([@b39-ehp0113-000969]; [@b63-ehp0113-000969]). \[Ca^2+^\]~i~ oscillations have recently been described as finely regulated by 17β-estradiol (17β-E~2~) in both α- and β-cells. In the glucagon-containing α-cells, 17β-E~2~ provokes the suppression of \[Ca^2+^\]~i~ oscillations generated by low glucose, whereas in β-cells the gonadal hormone potentiates Ca^2+^ signals ([@b52-ehp0113-000969]). In both types of cells the 17β-E~2~ effect is initiated after binding to a nonclassical membrane estrogen receptor (ncmER) ([@b40-ehp0113-000969]; [@b52-ehp0113-000969]).

Environmental estrogens are endocrine-disrupting chemicals (EDCs) that in many cases imitate the actions of the natural hormone 17β-E~2~, eliciting deleterious effects on humans and wildlife ([@b11-ehp0113-000969]; [@b23-ehp0113-000969]; [@b24-ehp0113-000969]; [@b25-ehp0113-000969]). It is well accepted that EDCs exert their effects after binding at the classical ER-α and ER-β, inducing classic nuclear actions ([@b21-ehp0113-000969]; [@b34-ehp0113-000969]). Most of the effects described through the classical pathway occur at micromolar concentrations of EDCs. Evidence accumulated in the last few years indicates that EDCs imitate 17β-E~2~ actions through alternative pathways, which in some cases are unrelated to classical ERs ([@b34-ehp0113-000969]; [@b36-ehp0113-000969]; [@b71-ehp0113-000969]). Some of these pathways are activated at picomolar and nanomolar concentrations of EDCs ([@b6-ehp0113-000969]; [@b40-ehp0113-000969]; [@b48-ehp0113-000969]; [@b72-ehp0113-000969]).

We have described in pancreatic β-cells the effect of two EDCs: bisphenol A (BPA), found in polycarbonate plastic, in the content of food in coated cans, dental sealant, and composites ([@b5-ehp0113-000969]; [@b59-ehp0113-000969]), and diethylstilbestrol (DES), a synthetic estrogen used between the 1940s and the 1970s to prevent miscarriages ([@b43-ehp0113-000969]). Both bind to an ncmER to induce \[Ca^2+^\]~i~ signals at concentrations as low as 10^−9^ M ([@b40-ehp0113-000969]). In addition, 10^−9^ M BPA via the ncmER activates the transcription factor CREB ([@b48-ehp0113-000969]).

In pancreatic β-cells, we used laser scanning confocal microscopy to study \[Ca^2+^\]~i~ movements as an index of changes in intra-cellular signaling because \[Ca^2+^\]~i~ signals are involved in a large number of signaling processes, from secretion to gene expression ([@b50-ehp0113-000969]; [@b60-ehp0113-000969]). We used pancreatic α-cells within freshly isolated islets of Langerhans, the physiologic unit of the endocrine pancreas. This preparation is similar to the actual physiologic situation as demonstrated by \[Ca^2+^\]~i~ and electrical activity recordings *in vivo* ([@b13-ehp0113-000969]; [@b57-ehp0113-000969]). Moreover, this methodology excels when applied to this particular type of cell, which is very difficult to work with because of its scarcity (α-cells represent only about 10--20% of the total number of islet cells, i.e., \~ 150--300 cells per islet). Using this approach, we demonstrated that low doses of BPA and DES imitate the E~2~-induced blockade of Ca^2+^ signals in glucagon-releasing α-cells within intact islets of Langerhans. This effect is mediated by the interaction with an ncmER and involves G-proteins, nitric oxide synthase (NOS), and cGMP-dependent protein kinase (PKG).

Materials and Methods
=====================

Materials.
----------

We obtained Fluo-3 AM from Molecular Probes Inc. (Leiden, the Netherlands); ICI182,780 and 1H-\[1,2,4\] oxadiazolo\[4,3-a\] quinoxalin-1-one (ODQ) from Tocris Cookson Ltd. (Avonmouth, UK); and KT-5823 from Alomone Labs (Jerusalem, Israel). Other chemicals were obtained from Sigma (Madrid, Spain). We also obtained estradiol--horseradish peroxidase (E-HRP) from Sigma; however, it is not available from this company at the present time.

Measuring intracellular calcium in α-cells within intact islets of Langerhans.
------------------------------------------------------------------------------

Swiss albino OF1 male mice (8--10 weeks of age) were killed by cervical dislocation according to national guidelines provided by our animal house. An internal animal care and use committee reviewed and approved the method used.

Pancreatic islets of Langerhans were isolated by collagenase digestion as previously described ([@b41-ehp0113-000969]) and loaded with 5 μM Fluo-3 AM for at least 1 hr at room temperature. Loaded islets were kept in a medium containing 115 mM NaCl, 10 mM NaHCO~3~, 5 mM KCl, 1.1 mM MgCl~2~, 1.2 mM NaH~2~PO~4~, 2.5 mM CaCl~2~, and 25 mM HEPES, plus 1% albumin and 5 mM [d]{.smallcaps}-glucose, continuously gassed with a mixture of 95% O~2~ and 5% CO~2~ (pH 7.35). Islets were perfused at a rate of 1 mL/min with a modified Ringer solution containing 120 mM NaCl, 5 mM KCl, 25 mM NaHCO~3~, 1.1 mM MgCl~2~, and 2.5 mM CaCl~2~ (pH 7.35 when gassed with 95% O~2~ and 5% CO~2~). It took 30--60 sec to change the bath volume completely; this may explain the different response times for some of the experiments.

Calcium records in individual cells were obtained by imaging intracellular calcium under a Zeiss PASCAL5 confocal microscope using a Zeiss 40× oil-immersion lens, with numerical aperture 1.3 (Zeiss, Jena, Germany). Images were collected at 2-sec intervals, and the time course of fluorescent signals from individual cells were measured using the Zeiss LSM software package (Zeiss, Heidelberg, Germany). Experiments were performed at 34°C. Results were plotted using commercially available software (Sigmaplot; Jandel Scientific, Erkrath, Germany) in which the change in fluorescence (ΔF) is expressed as a percentage of the basal fluorescence (F~0~) observed in the absence of stimulus or during the intervals between spikes. α-Cells within the islets were identified by their \[Ca^2+^\]~i~ oscillatory pattern in 0.5 mM glucose ([@b38-ehp0113-000969]; [@b49-ehp0113-000969]). The frequency of \[Ca^2+^\]~i~ oscillations was calculated during a period of 2--4 min before stimuli application (control), and the frequency was measured during 5 min of stimuli application calculated over the period from minute 5 to minute 10 after stimuli were applied. Because a stable baseline before stimuli application was nonexistent, a spike was defined by a rapid increase in \[Ca^2+^\]~i~ higher than twice the SD of background signals at the intervals between spikes. Spikes were counted manually.

Cell isolation and culture.
---------------------------

Isolated islets were dispersed into single cells and cultured as previously described ([@b41-ehp0113-000969]). Briefly, islets were disaggregated into single cells with trypsin. Cells were then centrifuged, resuspended in RPMI 1640 culture medium supplemented with 10% fetal calf serum, 200 U/mL penicillin, 0.2 mg/mL streptomycin, 2 mM [l]{.smallcaps}-glutamine, and 11 mM glucose and plated on poly- [l]{.smallcaps}-lysine--coated glass coverslips. Cells were kept at 37°C in a humidified atmosphere of 95% O~2~ and 5% CO~2~ for 24 hr.

Estradiol-HRP binding assay.
----------------------------

The E-HRP binding assay was performed as previously described ([@b40-ehp0113-000969]; [@b52-ehp0113-000969]). Briefly, after 24 hr in culture, cells were gently fixed to avoid permeabilization and exposed overnight to 4.5 μg/mL E-HRP plus the testing reagent at 4°C. This was the appropriate concentration of E-HRP to obtain a suitable labeling of the cell membrane. E-HRP binding was visualized by the precipitate formed when reacting with 3,3′-diaminobenzidine tetrahydrochloride (DAB) in the presence of urea hydrogen peroxide and CoCl~2~ for 15 min \[SIGMA FAST DAB with metal enhancer tablet set (Co-DAB)\]. The light absorbed by the precipitate was measured; the lower the percentage of absorbed light, the higher the competition for an E-HRP binding site. The quantity of E-HRP bound is expressed as the percentage of absorbed light compared with the control condition. In order to obtain an appropriate staining background, incubation and developmental procedures with peroxidase were performed in identical conditions. All of the chemicals tested for competition with E-HRP were used in a concentration 300-fold higher than that of E-HRP.

Immunocytochemistry.
--------------------

α-Cells were identified using antiglucagon antibody labeling. After staining with E-HRP and Co-DAB, the cells were permeabilized with 1% Triton X-100 for 2 min, and immunocytochemistry was performed as previously described ([@b52-ehp0113-000969]).

Results
=======

Effect of EDCs and E~2~ on low-glucose--induced \[Ca^2+^\]~i~ oscillations.
---------------------------------------------------------------------------

To investigate the effect of E~2~ and EDCs in pancreatic α-cells, \[Ca^2+^\]~i~ recordings were obtained from intact islets of Langerhans ([Figure 1A](#f1-ehp0113-000969){ref-type="fig"}) loaded with the fluorescent calcium-sensitive dye Fluo-3 and imaged using laser scanning confocal microscopy ([Figure 1B](#f1-ehp0113-000969){ref-type="fig"}). Although only the periphery of the islet is loaded, as previously described ([@b38-ehp0113-000969]; [@b52-ehp0113-000969]), all the different types of cells within the islet are represented and can be easily identified by their \[Ca^2+^\]~i~ response to glucose ([@b38-ehp0113-000969]; [@b49-ehp0113-000969]). Pancreatic α-cells are distinguished by their particular oscillatory \[Ca^2+^\]~i~ pattern in the absence of glucose, which diminishes as the glucose concentration is increased ([Figure 1C](#f1-ehp0113-000969){ref-type="fig"}).

Typical α-cells presented a \[Ca^2+^\]~i~ oscillatory pattern in the absence of glucose, which was completely suppressed by 1 nM BPA in almost 50% (20 of 41) of the cells ([Figure 2A,D](#f2-ehp0113-000969){ref-type="fig"}) and by 1 nM DES in 31% of the cells (14 of 45 cells; [Figure 2B,D](#f2-ehp0113-000969){ref-type="fig"}). In all the remaining cells, both EDCs largely reduced the frequency of \[Ca^2+^\]~i~ oscillations ([Figure 2E](#f2-ehp0113-000969){ref-type="fig"}). To calculate the average effect on the frequency of \[Ca^2+^\]~i~ ([Figure 2E](#f2-ehp0113-000969){ref-type="fig"}), an average of all cells was performed. The pesticide 1,1,1-trichloro-2-\[*o*-chlorophenyl\]-2,2\[*p*-chlorophenyl\] ethane (*o, p*′-DDT), was less active, producing a complete blockade in only 7% (3 of 41) of the cells tested ([Figure 2C,D](#f2-ehp0113-000969){ref-type="fig"}). The onset of the effect of BPA and DES was very rapid, and the decrease of the frequency of \[Ca^2+^\]~i~ oscillations was similar to the one obtained with E~2~ and the membrane-impermeable E-HRP ([Figure 2E,F](#f2-ehp0113-000969){ref-type="fig"}). We used a concentration of E-HRP that was equivalent to the molecules of E~2~. Because the effect was present at a concentration equivalent to 1 nM E~2~, the effect should be produced by the conjugated form; if free 17β-E~2~ was present, it would be in a much lower concentration. The effect of *o*,*p*′-DDT was significantly smaller than that of the other estrogenic compounds ([Figure 2E,F](#f2-ehp0113-000969){ref-type="fig"}). E~2~ and EDC effects were irreversible after 20 min in a solution of 0.5 mM glucose, as previously described for E~2~ ([@b52-ehp0113-000969]). The speediness of the action and the fact that E-HRP mimics the actions of E~2~, BPA, and DES indicate that these EDCs act through an E~2~ binding site, probably located at the plasma membrane.

A common membrane-binding site is shared by E~2~, BPA, and DES.
---------------------------------------------------------------

To further demonstrate the implication of a membrane binding site, we used a binding assay method based on the interaction of E-HRP as a specific probe to detect E~2~ binding sites at the plasma membrane of nonpermeabilized cells. E-HRP bound to the plasma membrane is developed using DAB; the DAB-based primary reaction product of peroxidase was used as an indication of the amount of E-HRP bound to the estrogen-binding sites. This primary reaction product is highly absorptive of laser light at 543 nm and can be easily visualized with high contrast by using transmission laser scanning microscopy ([@b40-ehp0113-000969]). This assay has been combined with immunocytochemistry against glucagon performed afterward to study specifically the characteristics of the E~2~ binding site in glucagon-containing α-cells ([@b52-ehp0113-000969]). [Figure 3A](#f3-ehp0113-000969){ref-type="fig"} shows several E-HRP control cells after being developed with Co-DAB; two of them were identified as glucagon-containing α-cells by immuno-staining ([Figure 3D](#f3-ehp0113-000969){ref-type="fig"}). These control cells presented a black staining that absorbed the light of 543 nM from the laser beam ([Figure 3G](#f3-ehp0113-000969){ref-type="fig"}).

When DES was added at the same time as E-HRP, it decreased the binding of E-HRP to its binding site at the plasma membrane, producing a reduced amount of precipitate. This can be easily visualized by a lower light absorption ([Figure 3B,E](#f3-ehp0113-000969){ref-type="fig"}), and it has been quantified in [Figure 3G](#f3-ehp0113-000969){ref-type="fig"}. [Figure 3C](#f3-ehp0113-000969){ref-type="fig"} shows the basal level when α-cells are incubated only with HRP. This background level has been subtracted in all experiments.

[Figure 3G](#f3-ehp0113-000969){ref-type="fig"} shows that BPA, DES, and E~2~ bind to the same membrane-binding site. Remarkably, the pesticide *o*,*p*′-DDT, which was weaker in inducing the abolishment of \[Ca^2+^\]~i~ signals, presented a very low competition. This may indicate that the EDCs containing phenol groups, that is, DES and BPA, mimic the effects of 17β-E~2~, which also contains a phenolic A-ring in its structure, by binding at the same membrane-binding site. However, *o*,*p*′-DDT, which contains no hydroxylated moieties in its structure, was less potent.

To characterize whether the membrane-binding site is an ncmER, we tested whether actions of BPA, DES, and E~2~ were modified by the pure antiestrogen ICI182,780, which inhibits ER-mediated effects. [Figure 4](#f4-ehp0113-000969){ref-type="fig"} shows that the effects of BPA and DES were not modified by ICI182,780. In fact, BPA completely suppressed \[Ca^2+^\]~i~ oscillations in all the cells tested (*n* = 8, four islets), and DES blocked low-glucose--induced \[Ca^2+^\]~i~ oscillations in 10 of 13 cells (five islets), and in the remaining three cells it largely reduced the frequency of \[Ca^2+^\]~i~ oscillations ([Figure 4C](#f4-ehp0113-000969){ref-type="fig"}). ICI182,780 did not modify the frequency of low-glucose--induced \[Ca^2+^\]~i~ oscillations ([Figure 4C](#f4-ehp0113-000969){ref-type="fig"}): ICI182,780 controls ICI1--ICI3 range from 0.8/min to 1.4/min, well within the range described for 0.5 mM glucose ([Figure 2E](#f2-ehp0113-000969){ref-type="fig"}). This, along with the experiment described in [Figures 2](#f2-ehp0113-000969){ref-type="fig"} and [3](#f3-ehp0113-000969){ref-type="fig"}, strongly suggests that EDC effects are mediated by a membrane ER with a different pharmacologic profile than that of the classical ERs.

cGMP and PKG mediate rapid effects of BPA and E~2~.
---------------------------------------------------

The experiments described to this point suggested that the actions of BPA and DES are mediated through the same receptor as is 17β-E~2~ in α-cells. For that reason, we used BPA as the paradigmatic EDC in this system to further analyze the molecular pathway involved. Because we have previously described that cGMP and PKG were implicated in the case of the natural hormone ([@b52-ehp0113-000969]), we sought to study their effects on the action of BPA. Application of 10 μM 8-bromo-guanosine 3′,5′-cyclic monophosphate (8Br-cGMP) mimicked the effects of BPA, DES, and E~2~ on \[Ca^2+^\]~i~ oscillations ([Figure 5A](#f5-ehp0113-000969){ref-type="fig"}), as previously demonstrated ([@b52-ehp0113-000969]; [@b62-ehp0113-000969]). Given that the action of cGMP was probably mediated by PKG, we tested the action of 8Br-cGMP in cells pretreated with the membrane-permeable PKG inhibitor KT-5823 for 1 hr. Pretreatment with the PKG inhibitor did not have any effect on low-glucose--induced \[Ca^2+^\]~i~ oscillations ([Figure 5C](#f5-ehp0113-000969){ref-type="fig"}), but it almost completely blocked 8Br-cGMP action ([Figure 5B,C](#f5-ehp0113-000969){ref-type="fig"}).

When we used KT-5823 pretreated islets to test the effect of BPA, we found that the PKG inhibitor completely blocked BPA action ([Figure 6A,B](#f6-ehp0113-000969){ref-type="fig"}). Thus, KT-5823 does not alter \[Ca^2+^\]~i~ oscillations but prevents the suppression of low-glucose--induced \[Ca^2+^\]~i~ oscillations by BPA, indicating that BPA's effect is exerted by a cGMP/PKG-mediated mechanism, as has been demonstrated for the natural hormone 17β-E~2~ ([Figure 6C](#f6-ehp0113-000969){ref-type="fig"}).

Involvement of soluble guanylate cyclase and NOS in BPA and E~2~ actions.
-------------------------------------------------------------------------

In many cell types, increases in cGMP levels are due to the activation of soluble guanylate cyclase (GC) after NO generation by NOS. To test if this pathway was responsible for the BPA and E~2~ actions described above, we started by testing the effect of the NO donor sodium nitroprus-side (SNP). In cells that oscillate as usual in the presence of 0.5 mM glucose, SNP abolishes these \[Ca^2+^\]~i~ oscillations ([Figure 7A,C](#f7-ehp0113-000969){ref-type="fig"}). This effect resembles those produced by 8Br-cGMP and the estrogenic compounds BPA and E~2~. To check whether the NO effects on \[Ca^2+^\]~i~ oscillations were mediated by an increase in the intracellular levels of cGMP, we applied SNP after blocking GC activity with the selective inhibitor ODQ ([@b15-ehp0113-000969]). As shown in [Figure 7, B and C](#f7-ehp0113-000969){ref-type="fig"}, ODQ did not modify the average oscillatory frequency of \[Ca^2+^\]~i~ but completely blocked SNP action. Thus, blockade of GC activity prevented the inhibitory effect of SNP, suggesting that the action of NO is probably mediated by an increase in the intracellular levels of cGMP.

To prove that the cGMP/PKG-mediated actions of BPA and E~2~ described in [Figure 6](#f6-ehp0113-000969){ref-type="fig"} involved the upstream activation of a GC, we tested the effects of these compounds in ODQ-treated islets. In [Figure 8](#f8-ehp0113-000969){ref-type="fig"}, we demonstrate that the BPA and E~2~ inhibitions of low-glucose--induced \[Ca^2+^\]~i~ oscillations are completely suppressed in the presence of ODQ. Therefore, we have demonstrated that BPA and E~2~ actions involve the activation of a GC, probably by NO that generates cGMP, which in turns activates PKG.

To assess whether NOS is responsible for the generation of NO, we used the specific antagonist *N*-nitro- [l]{.smallcaps}-arginine methyl ester (L-NAME), which is known to block NOS activation in pancreatic islets ([@b1-ehp0113-000969]; [@b45-ehp0113-000969]; [@b56-ehp0113-000969]). As shown in [Figure 9](#f9-ehp0113-000969){ref-type="fig"}, L-NAME completely reversed the effect of BPA and E~2~ ([Figure 9A,C,E](#f9-ehp0113-000969){ref-type="fig"}), demonstrating that NOS activation and the concomitant NO increase are involved in the rapid actions of EDCs and E~2~ in pancreatic α-cells.

BPA and E~2~ effects involve a G-protein--coupled receptor.
-----------------------------------------------------------

To asses the role of G-proteins in the actions of EDC and E~2~ on \[Ca^2+^\]~i~ signals in α-cells, we used pertussis toxin (PTX), an inhibitor of Gα~i~ and Gα~o.~ After a 4 hr preincubation with 100 ng/mL PTX, no inhibitory effect of BPA and E~2~ was observed ([Figure 10A](#f10-ehp0113-000969){ref-type="fig"}). [Figure 10B](#f10-ehp0113-000969){ref-type="fig"} shows the effect of 1 nM BPA in an α-cell within an islet obtained from the same mouse and in the same conditions but in the absence of PTX. The results obtained from different experiments are summarized in [Figure 10E](#f10-ehp0113-000969){ref-type="fig"}. These results support the involvement of either a Gα~i~- or Gα~o~-coupled membrane receptor in the \[Ca^2+^\]~i~ regulation by BPA and E~2~.

Discussion
==========

The findings described in this article demonstrate that the endocrine disruptors BPA and DES imitate the circulating hormone 17β-E~2~ in suppressing low-glucose--induced \[Ca^2+^\]~i~ oscillations in pancreatic α-cells within intact islets of Langerhans. This rapid effect is observed in a preparation that is almost identical to the physiologic situation: intact islets of Langerhans used directly after their isolation. The \[Ca^2+^\]~i~ oscillatory pattern in β-cells observed *in vivo* ([@b13-ehp0113-000969]; [@b57-ehp0113-000969]) are identical to those described with the present method ([@b38-ehp0113-000969]; [@b58-ehp0113-000969]). We assume by these experiments performed in β-cells that both preparations behave in a similar manner.

It has been demonstrated that an ncmER is involved in the rapid nongenomic effects of estrogens in pancreatic α- and β-cells within intact islets of Langerhans ([@b40-ehp0113-000969]; [@b52-ehp0113-000969]). This ncmER is pharmacologically different from classical ERs because it is insensitive to antiestrogens such as tamoxifen and ICI182,780 ([@b39-ehp0113-000969]). Moreover, in pancreatic β-cells, BPA and DES bind to ncmER at doses similar to those of 17β-E~2~, inducing the potentiation of \[Ca^2+^\]~i~ oscillations ([@b40-ehp0113-000969]). In this article, we have shown that a common binding site exists for BPA, DES, and E~2~ in immunocytochemically identified α-cells. This binding site has a different pharmacologic profile than classical ERs: it binds BPA, DES, and E~2~ at a similar dose. Moreover, the action of these agents is triggered by remarkably low concentrations, 10^−9^ M. However, BPA is considered a weaker estrogen about 1,000- to 2,000-fold less potent than 17β-E~2~ when interacting with classical ERs located in the cell interior ([@b30-ehp0113-000969]; [@b31-ehp0113-000969]). This result, along with the absence of effect of the pure anti-estrogen ICI182,780, strongly indicates an action via a receptor other than the classical ER. In addition, the ncmER involved in the regulation of \[Ca^2+^\]~i~ by 17β-E~2~ in α-cells uses a cGMP/PKG-mediated pathway, the same one demonstrated here for BPA. Therefore, the receptor involved is very likely to be the same ncmER responsible for the 17β-E~2~ actions previously described in α- and β-cells ([@b40-ehp0113-000969]; [@b52-ehp0113-000969]).

In other types of cells E~2~ induced rapid cGMP/PKG-mediated actions. Upstream of cGMP/PKG, NOS is activated, producing NO and activating a GC that in turn increases cGMP levels ([@b9-ehp0113-000969]; [@b54-ehp0113-000969]; [@b74-ehp0113-000969]). In the present study, the suppression of low-glucose--induced \[Ca^2+^\]~i~ oscillations by E~2~ and BPA was reproduced by the NO donor SNP. This effect was completely blocked when the GC inhibitor ODQ was used, which indicates that NO is exerting its effect by activating a GC. When the GC inhibitor was used, E~2~ and BPA had no effect on low-glucose--induced \[Ca^2+^\]~i~ oscillations. Moreover, when the NOS inhibitor L-NAME was applied, E~2~ and BPA produced no effect on \[Ca^2+^\]~i~. This demonstrates that the actions of E~2~ and BPA are mediated by NOS activation, which produces NO and activates a GC. This is responsible for the increase in cGMP and the downstream activation of PKG that will likely block ion channels ([Figure 11](#f11-ehp0113-000969){ref-type="fig"}).

The results for the mechanism of action of E~2~ and BPA discussed above reinforce the idea that environmental estrogens imitate 17β-E~2~ actions not only through the classical pathway but also via other alternative pathways that do not necessarily involve classical ERs ([@b36-ehp0113-000969]). Alternative effects are triggered by classical and nonclassical ERs located in the cytosol and the plasma membrane ([@b37-ehp0113-000969]). Two main molecular pathways implicated are Src/PI3-Kinase/Akt and Src/Ras/ERKs, which subsequently may activate NOS, as well as other enzymes ([@b2-ehp0113-000969]; [@b8-ehp0113-000969]; [@b22-ehp0113-000969]; [@b35-ehp0113-000969]; [@b68-ehp0113-000969]). A number of studies have shown that both classical ERs associated with the plasma membrane and other unique membrane ERs activate G-proteins, initiating different signaling cascades that, in some cases, include the activation of NOS ([@b12-ehp0113-000969]; [@b47-ehp0113-000969]; [@b51-ehp0113-000969]; [@b73-ehp0113-000969]). In the present study, the suppression of low-glucose--induced \[Ca^2+^\]~i~ oscillations is blocked by the action of PTX, an inhibitor of Gα~i~ and Gα~o~, indicating that a G-protein--coupled receptor (GPCR) is involved. All known GPCRs have seven trans-membrane--spanning domains, whose intracel-lular domains propagate the signal from the receptor to the G-protein. It is possible that the ncmER found in the endocrine pancreas may be a seven-transmembrane domain GPCR, as is the case with the orphan receptor GPR30, which behaves as an estrogen membrane receptor in breast cancer cells ([@b65-ehp0113-000969]), and the new progestin receptor discovered in teleosts ([@b77-ehp0113-000969]). Another possibility is that a receptor with a different structure from GPCRs is coupled to a classical GPCR that activates Gα, which has been proposed for ER-α inendothelial cells ([@b73-ehp0113-000969]).

There are no extensive studies of endocrine disruptors acting through the same alternative pathways as the natural hormone 17β-E~2~. Nonetheless, evidence has accumulated in recent years in this direction ([@b36-ehp0113-000969]). The activation of ERKs (extracellular signal-regulated kinases) by several xeno-estrogens has been described in GH3/B6 pituitary tumor cells ([@b6-ehp0113-000969]). Recently, BPA and other xenoestrogens have been shown to mediate Ca^2+^ influx and pro-lactin release in GH3/B6 pituitary tumor cells at low concentrations ([@b72-ehp0113-000969]). Evidence shows that BPA activates NO synthesis in endothelial cells ([@b44-ehp0113-000969]), the release of dopamine in PC12 cells ([@b75-ehp0113-000969]), caspase-3 in neurons ([@b42-ehp0113-000969]), and ERKs and protein kinase C in immune system cells ([@b7-ehp0113-000969]). Because all of these actions are blocked by the pure antiestrogen ICI182,780, a classical ER should be involved.

Other actions triggered by endocrine disruptors are not blocked by ICI182,780, and they probably do not involve classical ERs. These include rapid effects of environmental pollutants, such as 4-octylphenol, nonylphenol, and *o*, *p*′-DDT, that inhibit Ca^2+^ channels in smooth muscle cells ([@b55-ehp0113-000969]); the activation of the nuclear factor of activated T-cell (NF-AT) signaling pathways ([@b32-ehp0113-000969]); and the activation of AP-1--mediated gene expression in cells that do not express classic ERs ([@b14-ehp0113-000969]). In human breast cancer cells, BPA modifies Ca^2+^ signals in a rapid manner ([@b69-ehp0113-000969]). In pancreatic β-cells, low concentrations of BPA activate the transcription factor CREB via a calcium-dependent mechanism that is activated by an ncmER ([@b48-ehp0113-000969]). CREB phosphorylation activated by BPA will bind to CRE (cAMP-responsive element) and in turn modulate DNA transcription. This suggests that the activation of steroid membrane receptors can produce cellular effects through genomic mechanisms.

There is a current debate regarding the concentration of EDCs needed to produce biologic effects in both humans and animals ([@b29-ehp0113-000969]; [@b70-ehp0113-000969]), especially because BPA is highly unstable in water and undergoes biodegradation to a less active compound ([@b61-ehp0113-000969]; [@b76-ehp0113-000969]). This would account for the BPA half-life of 2 days estimated in rivers ([@b76-ehp0113-000969]). Despite this, drinking water still has traces of BPA ([@b64-ehp0113-000969]), which have cellular effects ([@b25-ehp0113-000969]; [@b48-ehp0113-000969]; [@b70-ehp0113-000969]). In the endocrine pancreas, only nanomolar concentrations of BPA are required to modify the physiology of α- and β-cells. Furthermore, low concentrations of EDCs are enough not only to produce nongenomic effects but also to affect genomic pathways ([@b14-ehp0113-000969]; [@b48-ehp0113-000969]).

Ca^2+^ signals control many cellular processes, including secretion and gene expression. In pancreatic α-cells, glucagon release is Ca^2+^ dependent. In the absence of glucose, α-cells present an oscillatory \[Ca^2+^\]~i~ pattern that triggers glucagon secretion; this pattern is suppressed as the concentration of glucose is increased ([@b38-ehp0113-000969]), and a diminished glucagon secretion can be expected ([@b28-ehp0113-000969]). Unlike β-cells, α-cells are not synchronized ([@b38-ehp0113-000969]). Therefore, α-cells are subject to their individual sensitvity to stimuli, including low glucose. This may explain the heterogeneity in response to 17β-E~2~ and environmental estrogens. Like for low glucose, some α-cells respond to estrogen and xenoestrogens with complete blockade of calcium oscillations, whereas other cells only decrease the frequency of such oscillations ([@b38-ehp0113-000969]). The reason may be different levels of ncmER or any of the steps along the signaling pathway responsible for this effect. The effect of BPA and DES we observed is similar to the one produced by glucose, the suppression of the \[Ca^2+^\]~i~ movements that, in turn, decrease glucagon release ([@b38-ehp0113-000969]).

A disruption of glucose signaling process in α-cells by endocrine disruptors may have important implications for normal physiology. Glucagon acts via a seven-transmembrane domain GPCR ([@b26-ehp0113-000969]), which has been identified in multiple tissues including liver, brain, kidney, intestine, adipose tissue, and pancreas ([@b10-ehp0113-000969]; [@b27-ehp0113-000969]). The main physiologic role of glucagon is to stimulate the hepatic glucose output, increasing glycemia. This provides the major counter-regulatory mechanism for insulin by maintaining the glucose homeostasis in blood. It also has an important effect in inducing lipolysis and the release of fatty acids from adipose tissue when blood glucose is low. In the present study, E~2~, BPA, and DES all decrease α-cell signaling when glucose is low. This effect should diminish glucogenolysis as well as lipolysis and fatty acid release from adipocytes, contributing to a higher adiposity.

Therefore, the signaling pathway underlying the effects of EDCs described in this study reinforces the existence of a new scenario that explains some of the low-dose effects of EDCs: an action through new binding sites that rapidly activate different signaling cascades outside the cell nucleus. Furthermore, it describes the possibility that low doses of EDCs affect the normal physiology of the endocrine pancreas, altering the regulation of glucose and lipid metabolisms.
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![Fluorescence changes monitored from individual cells within intact islets of Langerhans. (*A*) Transmission image of an intact islet of Langerhans. (*B*) Color image of the same islet of Langerhans shown in *A* loaded with the calcium-sensitive dye Fluo-3 and exposed to 0.5 mM glucose; bar = 20 μm (color scale: blue, low calcium; red, high calcium). (*C*) Islets exposed to 0.5 mM glucose were switched to 11 mM glucose, as indicated by the bars above the trace. Note that the low-glucose oscillatory pattern is suppressed in the presence of a high glucose concentration (11 mM).](ehp0113-000969f1){#f1-ehp0113-000969}

![Effect of EDCs on \[Ca^2+^\]~i~ in pancreatic α-cells within the islets of Langerhans in response to 1 nM BPA (*A*), 1 nM DES (*B*), and 1 nM *o*, *p*′-DDT (*C*), in the presence of 0.5 mM glucose. (*D*) Percentage of cells with a complete blockade of \[Ca^2+^\]~i~ oscillations 5 min after application of stimuli. (*E*) Effect on the frequency of \[Ca^2+^\]~i~ oscillations after the stimuli were applied for 5 min and calculated over a 5--10 min period. G1--G5 are the frequencies of \[Ca^2+^\]~i~ in the presence of 0.5 mM glucose measured during a 2--4 min interval before stimuli application, and E~2~, HRP, BPA, EDS, and DDT represent the frequency values after 5 min application of the compound (see "Materials and Methods" for details). (*F*) Frequency (%) of \[Ca^2+^\]~i~ after stimuli compared with control conditions. Note that the decrease in the frequency is 80% in the presence of 1 nM BPA. Error bars in *E* and *F* indicate SE.\
\**p* \< 0.01, \*\**p* \< 0.0001, Student *t*-test, comparing each stimulus with its own control.](ehp0113-000969f2){#f2-ehp0113-000969}

![Binding assays with E-HRP and HRP and competition with E~2~, BPA, DES, and DDT. (*A--C*) Transmission images of nonpermeabilized pancreatic cells with E-HRP or HRP developed using Co-DAB: (*A*) cells incubated with E-HRP as control, (*B*) competition of 30 μM DES for the binding site of E-HRP, and (*C*) background staining with 100 nM HRP. (*D--F*) Glucagon-secreting cells identified by immunocytochemistry: (*D*) identification of the α-cells present in (*A*), (*E*) the same α-cell as in (*B*), and (*F*) the same cell as in (*C*) stained with antiglucagon antibody. (*G*) Competition for E-HRP binding site at the plasma membrane by 30 μM E~2~, BPA, DES, and DDT. Background binding obtained with 100 nM HRP has been subtracted. Data are from three duplicate experiments, expressed as mean + SE. Bars = 5 μm.](ehp0113-000969f3){#f3-ehp0113-000969}

![Effects of the pure antiestrogen ICI182,780 (1 μM) on 1 nM BPA (*A*) and 1 nM DES (*B*) action on low-glucose--induced \[Ca^2+^\]~i~ oscillations. ICI182,780 was perfused for at least 20 min before stimuli were added, and it was maintained during the whole period. (*C*) Mean frequencies in \[Ca^2+^\]~i~ oscillations in the presence of ICI182,780 (ICI) for each experiment (ICI1--ICI3) and in the presence of each stimulus. Results are representative of at least eight cells from four different islets, expressed as mean ± SE.\
\**p* \< 10^−5^, Student *t*-test comparing each stimulus with its own control.](ehp0113-000969f4){#f4-ehp0113-000969}

![Effects of 8Br-cGMP on EDCs and E~2~ via PKG. (*A*) Exposure to 10 μM 8Br-cGMP dramatically reduces the frequency of low-glucose--induced \[Ca^2+^\]~i~ oscillations. (*B*) After incubation with the specific PKG inhibitor KT-5823 (1 μM), 8Br-cGMP fails to evoke the marked reduction in \[Ca^2+^\]~i~ oscillations shown in (*A*). (*C*) Mean frequency values collected in the presence of 0.5 mM glucose (G), 8Br-cGMP plus 0.5 mM glucose (8Br-cGMP), KT-5823 (KT), and 8Br-cGMP plus KT-5823 (8Br-cGMP + KT). Results are representative of at least five cells in four different islets, expressed as mean ± SE.](ehp0113-000969f5){#f5-ehp0113-000969}

![Effects of BPA on \[Ca^2+^\]~i~ oscillations through a PKG-mediated mechanism. (*A*) Low-glucose--induced \[Ca^2+^\]~i~ oscillations blocked by 1 nM BPA. (*B*) Frequency of \[Ca^2+^\]~i~ oscillations were not reduced by BPA in an islet from the same preparation and maintained in the same conditions but pretreated with and exposed to the PKG inhibitor KT-5823 (1 μM). (*C*) Mean frequency values of 0.5 mM glucose before application of either BPA (G1) or E~2~ (G2), in the presence of 1 nM BPA or 1 nM E~2~, as in (*A*)*,* or in the presence of 1 μM KT-5823 plus 0.5 mM glucose (KT); KT plus 1 nM BPA (BPA + KT), and KT plus 1 nM 17β-E~2~ (E~2~ + KT) as in (*B*). Results are representative of at least 12 cells from nine different islets, expressed as mean ± SE.\
\**p* \< 0.0001, Student *t*-test comparing E~2~ with glucose or BPA with glucose.](ehp0113-000969f6){#f6-ehp0113-000969}

![Effects of ODQ on SNP action. (*A*) SNP (100 μM) produces a rapid blockade of low-glucose--induced \[Ca^2+^\]~i~ oscillations. (*B*) When SNP (100 μM) is applied in the presence of ODQ (10 μM), the frequency of \[Ca^2+^\]~i~ oscillations does not vary compared with that observed in the presence of ODQ alone. (*C*) Mean frequency values of 0.5 mM glucose (G) and 100 μM SNP as in (*A*)*,* and 0.5 mM glucose plus ODQ (ODQ), and ODQ plus SNP (SNP + ODQ) as in (*B*). Results are representative of at least four cells in four different islets, expressed as mean ± SE.\
\**p* \< 10^−5^, Student *t*-test comparing E~2~ with G1 and BPA with G2.](ehp0113-000969f7){#f7-ehp0113-000969}

![Effect of E~2~ and BPA involving a GC. (*A*) When 1 nM 17β-E~2~ is applied in the presence of 10 μM ODQ, the \[Ca^2+^\]~i~ oscillatory pattern is not modified. (*B*) Control experiment performed with an islet from the same preparation and maintained in the same conditions as in (*A*) but without ODQ. (*C*) Treatment with 10 μM ODQ prevents the effect of 1 nM BPA. (*D*) Control experiment performed with an islet from the same preparation and maintained in the same conditions as in (*C*) but without ODQ. (*E*) Mean frequency values for experiments as in (*A*): 0.5 mM glucose and 10 μM ODQ (ODQ1), 1 nM 17β-E~2~ in the presence of 10 μM ODQ (ODQ + E~2~); experiments as in (*B*): 0.5 mM glucose (G1), 1 nM 17β-E~2~; experiments as in (*C*): 0.5 mM glucose and 10 μM ODQ (ODQ2), 1 nM BPA in the presence of ODQ (ODQ + BPA); experiments as in (*D*): 0.5 mM glucose (G2), 1 nM BPA. Results are representative of at least six cells from five different islets, expressed as mean ± SE.\
\**p* \< 10^−5^, Student *t*-test comparing E~2~ with G1 and BPA with G2.](ehp0113-000969f8){#f8-ehp0113-000969}

![The NOS blocker L-NAME inhibits E~2~ and BPA actions. (*A*) When 1 nM 17β-E~2~ is applied in the presence of 100 μM L-NAME, the \[Ca^2+^\]~i~ oscillatory pattern is not modified. (*B*) Control experiment performed with an islet from the same preparation and maintained in the same conditions as in (*A*) but without L-NAME. (*C*) Treatment with 100 μM L-NAME prevents the effect of 1 nM BPA. (*D*) Control experiment performed with an islet from the same preparation and maintained in the same conditions as in (*C*) but without L-NAME. (*E*) Mean frequency values for experiments as in (*A*): 0.5 mM glucose and 100 μM L-NAME (L-NAME1), 1 nM 17β-E~2~ in the presence of 100 μM L-NAME (E~2~ + NAME); experiments as in (*B*): 0.5 mM glucose (G1), 1 nM 17β-E~2~; experiments as in (*C*): 0.5 mM glucose and 100 μM L-NAME (L-NAME2), 1 nM BPA in the presence of L-NAME (BPA + NAME); experiments as in (*D*): 0.5 mM glucose (G2), 1 nM BPA. Results are representative of at least 10 cells from eight different islets, expressed as mean ± SE.\
\**p* \< 10^−5^, Student *t*-test comparing E~2~ with G1 and BPA with G2.](ehp0113-000969f9){#f9-ehp0113-000969}

![E~2~ and BPA action is PTX sensitive. (*A*) Treatment of cells with the G-protein inhibitor PTX (100 ng/mL) for 4 hr completely abolishes 1 nM 17β-E~2~ action on \[Ca^2+^\]~i~ oscillations. (*B*) A control experiment performed with an islet from the same preparation and maintained in the same conditions as in (*A*) but without PTX. (*C*) Treatment with PTX prevents the effect of 1 nM BPA. (*D*) Control experiment performed with an islet from the same preparation and maintained in the same conditions as in (*C*) but without PTX. (*E*) Mean frequency values for experiments as in (*A*): 0.5 mM glucose and PTX (PTX1), 1 nM 17β-E~2~ in the presence of PTX (E~2~ + PTX); experiments as in (*B*): 0.5 mM glucose (G1), 1 nM 17β-E~2~; experiments as in (*C*): 0.5 mM glucose and PTX (PTX2), 1 nM BPA in the presence of PTX (BPA + PTX); experiments as in (*D*): 0.5 mM glucose (G2), 1 nM BPA, Results are representative of at least 10 cells from five different islets, expressed as mean ± SE.\
\**p* \< 10^−5^, Student *t*-test comparing E~2~ with G1 and BPA with G2.](ehp0113-000969f10){#f10-ehp0113-000969}

![Hypothetical model of the molecular pathway involved in E~2~-induced \[Ca^2+^\]~i~ regulation in α-cells. Abbreviations: G, G-protein; P~i~, intra-cellular phosphate. 17β-E~2~ and EDCs activate a PTX-sensitive pathway, indicating either that a G-protein--coupled receptor (GPCR) is involved or that a receptor with a different structure from GPCRs is coupled to a classical GPCR that activates a G-protein. This receptor is coupled in a yet undetermined manner with NOS, which generates NO. This activates soluble GC, which increases cGMP levels, which activates PKG, regulating ion channels and producing the abolishment of low-glucose--induced \[Ca^2+^\]~i~.](ehp0113-000969f11){#f11-ehp0113-000969}
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